USA - NASDAQ:SABS - US78397T2024 - Common Stock
We assign a fundamental rating of 1 out of 10 to SABS. SABS was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of SABS have multiple concerns. SABS is valied quite expensively at the moment, while it does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.99% | ||
| ROE | -308.38% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.05 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.02
-0.01 (-0.33%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 274.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.62 | ||
| P/tB | 2.62 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.99% | ||
| ROE | -308.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | -10.05 |
ChartMill assigns a fundamental rating of 1 / 10 to SABS.
ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.
SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 0 / 10.
The financial health rating of SAB BIOTHERAPEUTICS INC (SABS) is 0 / 10.